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An important new area of antidepressant drug development involves targeting the nicotinic acetylcholine receptor (nAChR). This
receptor, which is distributed widely in regions of the brain associated with depression, is also implicated in other important
processes that are relevant to depression, such as stress and inﬂammation. The two classes of drugs that target nAChRs can be
broadly divided into mecamylamine- and cytisine-based compounds. These drugs probably exert their eﬀects via antagonism at
α4β2 nAChRs, and strong preclinical data support the antidepressant eﬃcacy of both classes when used in conjunction with other
primary antidepressants (e.g., monoamine reuptake inhibitors). Although clinical data remain limited, preliminary results in this
area constitute a compelling argument for further evaluation of the nAChR as a target for future antidepressant drug development.
1.Introduction
Depression is one of the most common psychiatric ill-
nesses in the world and has a signiﬁcant public health
impact. Despite the abundance of medications available,
many aﬀected patients do not achieve relief. In the largest
comparative eﬃcacy study of antidepressant treatment, the
Sequenced Treatment of Alternatives to Relieve Depression
(STAR∗D) [1], about half of patients receiving initial
treatment with antidepressants responded, but only a third
reached remission, and up to a third never reached remission
despite multiple trials of various medications and combi-
nations. Most of the antidepressant drugs used in STAR∗D
directly increase synaptic availability of monoamines, often
viareuptakeinhibition. Clearly,newandbetterinterventions
that utilize novel mechanisms of action are needed.
Nicotinic acetylcholine receptor (nAChR) modulation is
an area with signiﬁcant promise for future antidepressant
drug development. The nAChR literature builds upon stud-
ies from the 1970s that advanced a cholinergic theory of
depression, in which excessive cholinergic signaling could
leadtodepressivesymptoms.Thisareaofresearchwaslargely
abandoned due to issues regarding safety and tolerability of
the compounds available at that time. More recently, with
the development of new molecules targeting this system,
signiﬁcantinterestintheantidepressantpropertiesofnAChR
modulation has reemerged. This paper reviews the available
literature on the use of nAChR modulators for treating
depression, building on previous reports [2]. Their use for
other indications, such as smoking cessation and cognitive
enhancement, has been addressed elsewhere [3–6].
2.The NicotinicAcetylcholineReceptor
In their common ability to respond to acetylcholine binding,
nAChRs are functionally related to muscarinic acetylcholine
receptors (mAChRs). However, whereas mAChRs activate
ion channels via G-protein coupling, nAChRs are ligand-
gated ion channels and exhibit aﬃnity for nicotine as well as
acetylcholine. Activated nAChRs cause an inﬂux of cations,
which aﬀect membrane polarity and intracellular messenger
cascades [7]. nAChRs are distributed throughout both the
peripheral and central nervous systems, although the focus
here is on central nervous system (CNS) nAChRs. Formed of
ﬁve pentameric units, nAChRs can be categorized as either
high or low aﬃnity. High-aﬃnity nAChRs are heteromers
of α-a n dβ-subunits, are antagonized by compounds2 The Scientiﬁc World Journal
such as dihydro-β-erythroidine and mecamylamine and
are stimulated by low doses of the α4β2 partial agonist
varenicline. Low-aﬃnity nAChRs, on the other hand, are α
homopentamersandareantagonizedbyα-bungarotoxinand
methyllycaconitine [7].
CNS nAChRs are widely distributed throughout brain
regions associated with depression, such as the ventral
tegmental area, locus coeruleus, and dorsal raphe nucleus.
Their primary action is thought to be in the regulation
of other neurotransmitter systems [8], particularly do-
pamine, via direct [9] and indirect eﬀects [7, 10–13], and
the n-methyl-D-aspartate (NMDA) glutamatergic system
[14]. nAChRs are also involved in other neurobiological
systems that are dysregulated in depression, such as the
hypothalamic-pituitary-adrenal axis. nAChRs are found
on presynaptic terminals of corticotropin-releasing factor
(CRF) neurons [15], and nAChR antagonists can block CRF
release [16]. Similarly, nAChRs appear to play a role in
inﬂammation, which is the subject of increasing interest
with regard to depression [17]. nAChRs regulate the so-
called cholinergic ascending anti-inﬂammatory pathway, in
whichactivationofthevagusnervediminishesinﬂammation
through decreased peripheral macrophage activity mediated
via α7n A C h R s[ 18, 19].
3. nAChRsand Depression:Antidepressant
Effects of Nicotine
Nicotine, the classic nAChR ligand, has been demonstrated
to have antidepressant properties in both preclinical and
clinical studies. In rodents, several studies of nicotine
administration have identiﬁed antidepressant-like eﬀects
during the forced swim test (FST) and tail suspension test
(TST) [20–23], two preclinical models used to investigate
potential antidepressant eﬀects of candidate compounds [24,
25]. Complementing these experiments, clinical studies have
shown that transdermal nicotine can improve mood in both
depressed smokers [26] and nonsmokers [27]. Antidepres-
sant eﬀects of nicotine are thought to be due to initial
activation of the nAChR, followed by rapid desensitization
that leads to long-term antagonism [28–32].
4. Targeting nAChRs for Depression
Most research targeting nAChRs for depression has focused
on several parent compounds and their derivatives. The two
principal compounds evaluated to date are mecamylamine,
a nonspeciﬁc nAChR antagonist, and the plant alkaloid
cytisine, which has been investigated for its eﬀects on α4β2
nAChRs. The following sections are organized by parent
compound, starting with a discussion of the preclinical
literature supporting use for depression, then followed by
clinical evidence, if available.
5.Mecamylamine
Mecamylamine is a nonselective and noncompetitive antag-
onist at nAChRs. Derived from camphene, mecamylamine
was ﬁrst developed in the 1950s and utilized clinically
as an antihypertensive agent [33], although its use was
limited by anticholinergic side eﬀects at therapeutic doses.
After preliminary clinical studies that showed eﬃcacy
for mecamylamine in augmenting the eﬃcacy of pri-
mary antidepressants [34], a number of preclinical studies
evaluated its use in animal models of depression. Popik
et al. [35] ﬁrst demonstrated that mecamylamine, combined
with the tricyclic antidepressant (TCA) imipramine or the
selective serotonin reuptake inhibitor (SSRI) citalopram,
improved immobility time during the FST. This study
also investigated dihydrobetaerythiodine, a selective α4β2
nAChR antagonist, which increased the antidepressant-like
eﬀects of imipramine. Other studies consistently showed
that racemic mecamylamine could improve performance on
the FST or TST, either alone [36–39] or in combination
with primary antidepressants [20, 37]. Administration of
the s-enantiomer of mecamylamine, s-mecamylamine, also
resulted in improvement in FST and behavioral despair
tests [40]. These eﬀects are driven by antagonism at the
α4β2 nAChR, as knockout mice for this speciﬁc subtype of
nAChR showed no eﬀect of mecamylamine administration
[37]. While most of these studies were positive, negative
ﬁndings were reported by Andreasen and Redrobe [20].
They found no eﬀect of mecamylamine when used alone
or in combination with citalopram; only citalopram had
signiﬁcant eﬀects on FST performance (Table 1).
These preclinical studies laid the foundation for further
clinical trials of mecamylamine as an augmenting agent for
the treatment of depression. Shytle et al. [34] ﬁrst showed
that mecamylamine improved depressive symptoms and
irritability in children and adolescents with Tourette’s disor-
der, a neuropsychiatric condition characterized by multiple
physical and vocal tics (i.e., stereotyped motor movements
or vocalizations) [41]. George et al. [42] subsequently con-
ducted an 8-week, double-blind, placebo-controlled trial
of mecamylamine augmentation, administering mecamy-
lamine 10mg/day augmentation to patients with at least
moderate depressive symptoms who had been on an SSRIfor
at least 3 months with little or no response. The investigators
additionally hypothesized that smokers would have a more
robust response to mecamylamine, as nAChRs are thought
to be upregulated in smokers due to chronic nicotine self-
administration [43]. Overall, mecamylamine augmentation
resulted in signiﬁcant improvement in depressive symptoms
compared to placebo. In contrast to the investigators’
hypothesis, there was a trend (P = 0.06) for nonsmoking
patients to have a greater response than smokers, suggesting
that mecamylamine might be more eﬃcacious in the former
group.
Larger commercial trials of racemic mecamylamine and
s-mecamylamineasaugmentationagentsfordepressionwere
subsequently conducted. While the results are not in the
public domain, outcomes from the racemic mecamylamine
trial were reportedly positive, and phase II results for s-
mecamylamine were also reportedly positive, with a large
eﬀect size [6]. However, preliminary reports from a large,
multicenter, double-blind phase III trial failed to meet the
primary endpoint of signiﬁcant improvement in depressiveThe Scientiﬁc World Journal 3
Table 1: Evidence for MEC/S-MEC in mouse models of depression.
Study Compound(s) MEC/s-MEC dose Results
Popik et al. [35] MEC + CTP
MEC + IMI 0.025mg/kg Improved FST
Rabenstein et al. [36] MEC 1mg/kg Improved FST and TST
Caldarone et al. [37] MEC 0.50, 0.75, or 1.0mg/kg Improved FST/TST
MEC + AMI Further improved FST/TST
Andreasen et al. [38]M E C 3 o r 1 0 m g / k g a Improved FST/TST
Andreasen and Redrobe [20] M E C+C T P 1 ,3m g / k g N oe ﬀect on FST/TST
MEC + REB
Mineur et al. [39]M E C 1 m g / k g I m p r o v e d F S T / T S T
Lippiello et al. [40]S - M E C 3 m g / k g I m p r o v e d F S T
Notes: a1–10mg/kg doses tested, and only doses at 3 and 10mg/kg with improved FST/TST.
Abbreviations: MEC: mecamylamine; CTP: citalopram; IMI: imipramine; AMI: amitriptyline: REB: reboxetine; S-MEC: s-mecamylamine; FST: forced swim
test; TST: tail suspension test.
symptoms [44]. There could be many reasons for this
negative result, including issues diﬀering eﬃcacy in smok-
ers versus nonsmokers. Cultural inﬂuences may also have
impacted clinical trial outcome measures, as the phase II
study was completed largely in India and, to a lesser extent,
the United States, whereas the phase III study was conducted
in European countries. Since this study is not in the public
domain,itisdiﬃculttoevaluatepossibleexplanationsforthe
negative results, and it would seem premature to dismiss the
potential antidepressant eﬀects of mecamylamine without
fuller access to the data.
6.CytisineandCytisine-BasedCompounds
6.1. Cytisine. Cytisine, a partial agonist at the α4β2n A C h R
[39], is extracted from the seeds of the Cytisus labornum
(Golden Rain Acacia) [45]. It was ﬁrst developed as an
inexpensive smoking cessation agent in former Eastern Bloc
countries in the 1950s and continues to be available as
an over-the-counter smoking cessation agent in Russia.
It constitutes the parent structure for other pyridine-like
compounds, such as varenicline, dianicline, and sazetidine.
Preclinical studies consistently have demonstrated an-
tidepressant-like eﬀects of cytisine in acute [39, 46]a n d
chronic [39] rodent models. Cytisine administration has
been linked to reduced expression of c-fos, an immediate
early gene transcription factor reﬂecting neuronal activity
[47] that downregulates in the context of chronic anti-
depressant treatment [48]. Other cytisine-based partial α4β2
nAChR agonists also have antidepressant-like eﬀects [46],
which further underscores the potential of this parent
compound for treating depression. To our knowledge, there
are no clinical studies investigating cytisine for depression,
although the one available smoking cessation study found
little eﬀect of the drug on either smoking cessation or
depressivesymptoms[49].Theseﬁndingscouldbeexplained
by cytisine’s limited ability to aﬀect CNS α4β2n A C h R s[ 50].
6.2. Varenicline. Varenicline, a partial agonist at the high-
aﬃnity α4β2 nAChR and full agonist at the α7n A C h R ,w a s
synthesized from its parent compound cytisine [51] in the
pursuit of novel drugs for smoking cessation. In preclin-
ical models, varenicline produced mild antidepressant-like
eﬀects during the FST, comparable to the SSRI sertraline
but less than the TCA amitriptyline [52]. However, when
administered in combination with sertraline, varenicline
signiﬁcantly improved FST performance. These eﬀects were
seen at lower doses of varenicline, which suggestedan inverse
dose-dependent eﬀect [52]. One further study found no
eﬀect of varenicline on the FST and TST, but varenicline
was administered in that study as a monotherapy, and most
doses tested (0.01–1mg/kg) were lower than those of other
studies (0.178–5.6mg/kg) [53]( Table 2). Large clinical trials
for smoking cessation showed improvement in depressive
symptoms associated with nicotine withdrawal [54, 55],
and subsequent examinations found improved mood and
cognition in subjects using varenicline for smoking cessation
[56]. A small open-label study of varenicline augmentation
in smokers with depression showed signiﬁcant improvement
in treatment-resistant patients [57].
One concern about the clinical use of varenicline has
been neuropsychiatric side eﬀects, such as increased depres-
sion or psychosis [60–62]. Although one report found that
varenicline was associated with an increased rate of such
events [63], other large studies have generally found no dif-
ferencebetweenvareniclineandothermedicationsforsmok-
ing cessation [64–67], ﬁndings that have been replicated in
studiessponsoredbytheU.S.FoodandDrugAdministration
[68]. An important consideration in evaluating this issue are
the adverse eﬀects upon mood of smoking cessation itself,
which has been shown to induce major depressive episodes
and suicidality in susceptible individuals [69].
6.3. Dianicline. Dianicline, also derived from cytisine, was
developed to target high-aﬃnity α4β2 nAChRs. The pre-
clinical proﬁle of dianicline is similar to that of varenicline,
with its ability to aﬀect dopamine release [70], although it
has relatively weak CNS penetration [71]. To our knowledge,
therearenostudiesevaluatingtheeﬀectofthiscompoundon
preclinical models of depression. The one available clinical4 The Scientiﬁc World Journal
Table 2: Evidence for cytisine and cytisine-based compounds in mouse models of depression.
Study Compound(s) CYT-compound dose Results
Mineur et al. [39] CYT 1.5mg/kga Improved FST/TST
Mineur et al. [46]
CYT 1, 1.5mg/kg Improved FST/TST
3-pyr-CYT Improved FST/TST
5-Br-CYT No eﬀect on FST/TSTb
Rollema et al. [52] VNCL 0.178, 0.56, 1, 1.78, 3.2, 5.6mg/kg Improved FST
VNCL + SERT 0.56, 5.6mg/kg Improved FSTc
Kozikowski et al. [58] SAZ-A 1mg/kg Improved FST
Turner et al. [53] VNCL 0.01, 0.1, 1mg/kg No eﬀect on FST
SAZ-A 1mg/kg Improved FSTd
Caldarone et al. [59] VNCL 0.3, 1, and 3mg/kg Improved FST
SAZ-A 1, 3, and 10mg/kg Improved FST
Notes: a0.2, 0.6, 1.0, and 1.5mg/kg CYT tested.
bNo CNS penetration.
cLow dose VNCL (0.56mg/kg) combined with low dose SERT (1.78mg/kg) produced no signiﬁcant eﬀect on FST performance.
dSAZ-A at doses of 0.05–0.5mg/kg had no eﬀect on FST performance.
Abbreviations: CYT: cytisine; 3-pyr-CYT: 3-[pyridin-3 -yl]-cytisine; 5-Br-CYT: 5-bromo-cytisine; VNCL: varenicline; SERT: sertraline; SAZ-A: sazetidine-A;
FST: forced swim test; TST: tail suspension test.
study of dianicline for smoking cessation was negative, with
little eﬀect on smoking outcomes or depressive symptoms
[72], as might be expected for a medication with weak CNS
penetration.
6.4. Sazetidine-A. Sazetidine-A is one of the newest com-
pounds targeting the α4β2 nAChR. Sazetidine-A is thought
to act in a diﬀerent manner than other cytisine analogues,
in that it binds to and desensitizes α4β2 nAChRs without
activation and acts principally on the β2 subunit [59, 73].
Kozikowski et al. [58] showed that acute administration
of sazetidine-A improved performance during the FST, to
a degree comparable to that of the TCA desipramine.
Several other recent studies have also shown antidepressant-
like eﬀects during the TST and FST [53, 59]( Table 2).
These promising ﬁndings have prompted investigations into
sazetidine-A analogues to evaluate potential antidepressant-
like activity [74–76]. To our knowledge, there are no studies
investigating sazetidine-A as an antidepressant augmenting
agent in preclinical models, nor are there clinical studies
investigating sazetidine-A for depression. However, given the
preclinical data for related compounds, we anticipate that
preclinical augmentation studies and clinical studies could
yield positive results.
7. α7 nAChRAgonists
The structurally distinct α7 nAChR, composed of ﬁve
identical α7 subunits, has been investigated for cognitive
disorders and schizophrenia [33], but older data suggest that
α7 agonists may have antidepressant activity. Studies from
the late 1990s suggested that α7 receptors were required for
the antidepressant eﬀects of the SSRI ﬂuoxetine [77], and
it is possible that preclinical antidepressant-like eﬀects of
varenicline may be, in part, due to agonism at this receptor.
Compounds targeting this nAChR have thus far generated
contradictory ﬁndings. PNU-282987 has been shown to
exhibit antidepressant-like eﬀects when administered in
combination with other antidepressants [78], but other
studies have not replicated this [79]. While these studies may
have been confounded by the speciﬁc mouse strains used
[80], it is unlikely this compound will be tested in humans
due to its potential for serious cardiac side eﬀects [81]. Other
α7 nAChR agonists that can improve FST performance, such
as SSR180711, are still under investigation [79]. Although
ﬁndings are still largely preliminary, they suggest that further
study of the role of this receptor in depression is warranted.
8. Conclusion
There is clear evidence that nAChRs are a promising area for
drug development in depression. Preclinical data document
the greatest potential for compounds that target the α4β2
nAChR, with the sazetidine-A ﬁndings suggesting that the
β2 component is necessary for antidepressant activity. All of
these drugs appear to be most eﬃcacious when administered
in combination with other antidepressants and at low
dosages. The relatively limited clinical data available to
date indicate unlikely eﬃcacy for cytisine and dianicline,
possible eﬃcacy for varenicline, and promising eﬃcacy for
mecamylamine as augmentation agents. It is unclear if these
compounds will have diﬀerential eﬃcacy in smoking or
nonsmoking populations, and this should be an important
consideration in future clinical trials. Taken together with
theknownlimitsofavailableantidepressantmedications,the
preclinical and clinical evidence provides a strong argument
for future antidepressant drug development targeting this
relatively unexplored receptor.The Scientiﬁc World Journal 5
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